arrow
N

Nicolò Danesin

university of padova
H指数:4
被引数:44

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

The use of Bruton-tyrosine kinase inhibitors in non-IgM lymphoplasmacytic lymphoma: a retrospective Italian study

布鲁顿酪氨酸激酶抑制剂在非IgM淋巴浆细胞样淋巴瘤中的应用:一项意大利回顾性研究

2026-09-250
PRE
Renal dysfunction in symptomatic Waldenström macroglobulinaemia: A nationwide Italian multicentre study

症状性华氏巨球蛋白血症的肾功能不全:一项意大利全国多中心研究

2026-03-080
OAAI
Ibrutinib or non-BTK inhibitor therapy in relapsed Waldenström Macroglobulinaemia? A real-life multicentre Italian study.

伊布替尼或非BTK抑制剂疗法在复发华氏巨球蛋白血症中的应用?一项意大利多中心真实世界研究。

2026-02-160
OAAI
Balancing safety and efficacy of Bendamustine plus anti CD20 regimens in elderly patients (> 70 y) with follicular lymphoma: a tertiary academic center experience

平衡老年(>70岁)滤泡性淋巴瘤患者接受 Bendamustine 联合抗CD20方案的安全性与有效性:一家三级学术中心的经验

2026-02-050
OAAI
An Uncommon Localization of Hairy Cell Leukemia: Central Nervous System Involvement and Response to Ibrutinib—A Case Report and a Review of the Literature

毛细胞白血病的不常见定位:中枢神经系统受累及伊布替尼的治疗反应——病例报告及文献综述

2025-10-310
OAAI
Serum soluble interleukin-2 receptor levels in hairy cell leukaemia as a marker of tumour burden with prognostic value and as a tool for disease monitoring

毛细胞白血病中血清可溶性白细胞介素-2受体水平作为肿瘤负荷标志物,具有预后价值,并作为疾病监测工具。

2025-07-290
OAAI
9p24/JAK2 rearrangements in myeloid neoplasms: from myelodysplastic syndromes to myeloid/lymphoid neoplasms with eosinophilia and tyrosine kinase gene fusions

9p24/JAK2重排与髓系肿瘤:从骨髓增生异常综合征到伴有嗜酸性粒细胞增多和酪氨酸激酶基因融合的髓系/淋巴系肿瘤

2025-03-240
PRE
First-line treatment of Waldenstrom's macroglobulinemia in Italy: A multicenter real-life study on 547 patients to evaluate the long-term efficacy and tolerability of different chemoimmunotherapy strategies
2024-11-190
OAAI
Baseline prognostic predictors in classical Hodgkin Lymphoma: a retrospective, single-center analysis on patients treated with PET/CT-guided ABVD

经典霍奇金淋巴瘤的基线预后预测因素: PET/CT引导下ABVD治疗患者的回顾性单中心分析

2024-09-050
OAAI
Protein kinase CK2α is overexpressed in classical hodgkin lymphoma, regulates key signaling pathways, PD-L1 and may represent a new target for therapy
2024-05-140
OAAI
Waldenström Macroglobulinemia in Very Elderly (≥75-year-old) Patients: A 33-year-retrospective Cohort Study in an Italian University Hospital
2023-10-014
OAAI